Monday, June 27, 2011
Alongside its agenda for
regulatory reform this week, BIO will roll out a series of proposals for
tax law and other financial legislation to bolster biotech capital formation.
Although BIO is working with
members of Congress to have its capital formation proposals introduced as part
of broader legislation that would include its regulatory innovation platform,
the tax and finance elements will have to be enacted separately, probably as
part of tax reform initiatives (see "Progressive Thinking for FDA,"